AETERNA ZENTARIS IS FOCUSED ON SERVING THE UNMET MEDICAL NEEDS OF PATIENTS with RARE ENDOCRINE DISEASES THROUGH ACQUIsition, DEVELOPment AND LICENSING ORPHAN PRODUCTs.
Aeterna Zentaris is a specialty biopharmaceutical company with laser-focus on developing and commercializing, principally through out-licensing arrangements, macimorelin, an orally available ghrelin agonist, to be used in the diagnosis of patients with Adult Growth Hormone Deficiency (AGHD). The prevalence and incidence of AGHD is not well known and awareness and diagnosis remains low. About 6,000 cases of AGHD are reported each year in the United States, with an estimated 50,000 diagnosed adults. In general, the prevalence and incidence of AGHD is not well investigated in Europe by epidemiological studies. However, the NHS has estimated the number of subjects with AGHD in England and Wales with 12,600 and the prevalence in UK with 1 case in 10,000 of the adult population. Considering a total population of 510 million for the European countries (EU-28), about 51,000 adults are estimated to be diagnosed with GHD.